Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib induction in ulcerative colitis
NCT03653026Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2018
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 44
01
Overview
Phase 3, randomised, double-blind trial in ulcerative colitis (UC) comparing Upadacitinib 45 mg with Placebo (2 arms). Primary endpoint: Clinical Remission Per Adapted Mayo Score at 8 weeks. Started Dec 2018; status: completed.
02
Drugs
upadacitinib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03653026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03653026.